Home World News Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring... World News Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 368 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Reflections from the World Cancer Congress November 30, 2022 Stopping the spread: A revolution in how we think about metastasis October 18, 2022 Snowboarder Wins Gold Medal At Winter Olympics After Beating Cancer February 8, 2022 Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause... August 4, 2026 Load more HOT NEWS Woman Helps Students With Special Needs Achieve Success After Graduation What to Expect During Recovery From a Bone Marrow Transplant: An... Thinking outside the chromosome – how ecDNA is challenging conventional thinking ESMO 2024 Press Conference
